BeiGene (NASDAQ:BGNE) Now Covered by Analysts at StockNews.com

Research analysts at StockNews.com assumed coverage on shares of BeiGene (NASDAQ:BGNE) in a research note issued on Sunday. The firm set a “hold” rating on the stock.

Several other equities research analysts also recently commented on the company. TD Cowen lifted their price objective on BeiGene from $254.00 to $260.00 and gave the stock a “buy” rating in a report on Wednesday, November 13th. Morgan Stanley reaffirmed an “overweight” rating and set a $300.00 price target on shares of BeiGene in a report on Tuesday, December 3rd. Finally, JPMorgan Chase & Co. boosted their price objective on shares of BeiGene from $200.00 to $235.00 and gave the company an “overweight” rating in a report on Tuesday, October 22nd. Three analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $253.69.

BeiGene Price Performance

The firm’s 50 day moving average price is $194.32 and its 200 day moving average price is $188.98. BeiGene has a fifty-two week low of $126.97 and a fifty-two week high of $248.16. The company has a current ratio of 1.93, a quick ratio of 1.72 and a debt-to-equity ratio of 0.05. The stock has a market capitalization of $18.03 billion, a PE ratio of -22.42 and a beta of 0.57.

BeiGene (NASDAQ:BGNE) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($1.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.11) by ($0.04). The business had revenue of $1 billion during the quarter, compared to the consensus estimate of $983.26 million. BeiGene had a negative net margin of 25.94% and a negative return on equity of 25.12%. The business’s revenue was up 28.2% compared to the same quarter last year. During the same period last year, the company posted $2.01 earnings per share. As a group, sell-side analysts anticipate that BeiGene will post -5.64 earnings per share for the current year.

Insider Transactions at BeiGene

In related news, Director Bros. Advisors Lp Baker sold 1,037,017 shares of BeiGene stock in a transaction on Monday, December 9th. The stock was sold at an average price of $187.27, for a total transaction of $194,202,173.59. Following the transaction, the director now directly owns 791,493 shares in the company, valued at approximately $148,222,894.11. The trade was a 56.71 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Xiaodong Wang sold 40,468 shares of the company’s stock in a transaction dated Tuesday, November 26th. The stock was sold at an average price of $190.10, for a total value of $7,692,966.80. The disclosure for this sale can be found here. Insiders have sold 1,119,245 shares of company stock worth $209,700,084 in the last quarter. Company insiders own 7.43% of the company’s stock.

Hedge Funds Weigh In On BeiGene

Large investors have recently added to or reduced their stakes in the company. Dimensional Fund Advisors LP lifted its position in shares of BeiGene by 118.9% in the second quarter. Dimensional Fund Advisors LP now owns 11,499 shares of the company’s stock valued at $1,649,000 after acquiring an additional 6,246 shares in the last quarter. Sei Investments Co. raised its stake in BeiGene by 3.6% during the 2nd quarter. Sei Investments Co. now owns 24,248 shares of the company’s stock valued at $3,459,000 after purchasing an additional 848 shares during the period. Point72 Asset Management L.P. purchased a new position in BeiGene in the 2nd quarter worth approximately $54,412,000. Squarepoint Ops LLC boosted its stake in BeiGene by 2.5% in the 2nd quarter. Squarepoint Ops LLC now owns 72,055 shares of the company’s stock worth $10,280,000 after purchasing an additional 1,743 shares during the period. Finally, Affinity Asset Advisors LLC boosted its stake in BeiGene by 33.9% in the 2nd quarter. Affinity Asset Advisors LLC now owns 110,000 shares of the company’s stock worth $15,694,000 after purchasing an additional 27,857 shares during the period. Hedge funds and other institutional investors own 48.55% of the company’s stock.

About BeiGene

BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC.